[1] Yang BL, Ren GS, Song EW, et al.  Current status and factors influencing surgical options for breast cancer in China: a nationwide cross-sectional survey of 110 hospitals[J]. Oncologist, 2020, 25(10): e1473-e1480.   doi: 10.1634/theoncologist.2020-0001
[2] 李囡, 林保和, 欧阳涛, 等.  99mTc-美罗华用于原发性乳腺癌前哨淋巴结活检[J]. 中国医学影像技术, 2009, 25(4): 681-684.   doi: 10.3321/j.issn:1003-3289.2009.04.047
Li N, Lin BH, Ouyang T, et al.  Sentinel lymph node biopsy with a novel sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast cancer[J]. Chin J Med Imaging Technol, 2009, 25(4): 681-684.   doi: 10.3321/j.issn:1003-3289.2009.04.047
[3] Li N, Wang XJ, Lin BH, et al.  Clinical evaluation of 99mTc-Rituximab for sentinel lymph node mapping in breast cancer patients[J]. J Nucl Med, 2016, 57(8): 1214-1220.   doi: 10.2967/jnumed.115.160572
[4] Charalampoudis P, Markopoulos C, Kovacs T.  Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: a comprehensive review of current data[J]. Eur J Surg Oncol, 2018, 44(1): 5-14.   doi: 10.1016/j.ejso.2017.10.215
[5] Canavese G, Bruzzi P, Catturich A, et al.  Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial[J]. Ann Surg Oncol, 2016, 23(8): 2494-2500.   doi: 10.1245/s10434-016-5177-4
[6] Mansel RE, Fallowfield L, Kissin M, et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial[J]. J Natl Cancer Inst, 2006, 98(9): 599-609.   doi: 10.1093/jnci/djj158
[7] 中国抗癌协会乳腺癌专业委员会.  中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609-680.   doi: 10.19401/j.cnki.1007-3639.2019.08.009
China Cancer Association Breast Cancer Specialized Committee.  Guidelines and norms for diagnosis and treatment of breast cancer of Chinese Anti-Cancer Association (2019 edition)[J]. China Oncol, 2019, 29(8): 609-680.   doi: 10.19401/j.cnki.1007-3639.2019.08.009
[8]

He PS, Li F, Li GH, et al. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review[J/OL]. BMC Cancer, 2016, 16(1):107[2020-06-03]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2137-0. DOI: 10.1186/s12885-016-2137-0.
[9] 张爱玲, 宾莲洁, 何广宁, 等.  单独或联合使用不同示踪剂在乳腺癌前哨淋巴结活检术中应用的对比研究[J]. 临床和实验医学杂志, 2018, 17(13): 1431-1435.   doi: 10.3969/j.issn.1671-4695.2018.13.027
Zhang AL, Bin LJ, He GN, et al.  A comparative study of single or combined use of different tracers in sentinel lymph node biopsy of breast cancer[J]. J Clin Exp Med, 2018, 17(13): 1431-1435.   doi: 10.3969/j.issn.1671-4695.2018.13.027
[10] 孙嘉忆, 张天一, 郭文斌.  吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活检中的应用价值[J]. 中国医师进修杂志, 2021, 44(3): 254-258.   doi: 10.3760/cma.j.cn115455-20201124-01672
Sun JY, Zhang TY, Guo WB.  The application value of indocyanine green combined with methylene blue in sentinel lymph node biopsy of breast cancer[J]. Chin J Postgrad Med, 2021, 44(3): 254-258.   doi: 10.3760/cma.j.cn115455-20201124-01672
[11] 田少林, 陈波.  亚甲蓝荧光在早期乳腺癌前哨淋巴结定位的临床价值[J]. 临床外科杂志, 2020, 28(11): 1025-1027.   doi: 10.3969/j.issn.1005-6483.2020.11.008
Tian SL, Chen B.  The clinical value of intraoperative methylene blue near-infrared fluorescence imaging and mapping in the sentinel lymph node biopsy of the early stage breast cancer[J]. J Clin Surg, 2020, 28(11): 1025-1027.   doi: 10.3969/j.issn.1005-6483.2020.11.008
[12] 丛斌斌, 孙晓, 宋现让, 等.  新型前哨淋巴结示踪剂的制备及动物实验研究[J]. 中国癌症杂志, 2016, 26(3): 245-250.   doi: 10.3969/j.issn.1007-3969.2016.03.007
Cong BB, Sun X, Song XR, et al.  The preparation and experimental study of a new sentinel lymph node tracer[J]. China Oncol, 2016, 26(3): 245-250.   doi: 10.3969/j.issn.1007-3969.2016.03.007
[13] Tian CL, Sun X, Cong BB, et al.  Murine model study of a new receptor-targeted tracer for sentinel lymph node in breast cancer[J]. J Breast Cancer, 2019, 22(2): 274-284.   doi: 10.4048/jbc.2019.22.e28
[14] 袁泉, 王伟.  纳米炭联合亚甲蓝示踪法在乳腺癌前哨淋巴结活检中的应用价值[J]. 中国当代医药, 2021, 28(5): 100-102, 107.   doi: 10.3969/j.issn.1674-4721.2021.05.027
Yuan Q, Wang W.  Application value of nano-carbon combined with methylene blue tracer method in sentinel lymph node biopsy of breast cancer[J]. China Mod Med, 2021, 28(5): 100-102, 107.   doi: 10.3969/j.issn.1674-4721.2021.05.027
[15] 李囡, 林保和, 欧阳涛, 等.  467例乳腺癌患者99Tcm-利妥昔单抗前哨淋巴结显像结果分析[J]. 中华核医学杂志, 2009, 29(1): 3-7.   doi: 10.3760/cma.j.issn.0253-9780.2009.01.002
Li N, Lin BH, Ouyang T, et al.  The results of sentinel lymph node imaging and biopsy with a novel lymphoscintigraphy agent 99Tcm-Rituximab in 467 breast cancer patients[J]. Chin J Nucl Med, 2009, 29(1): 3-7.   doi: 10.3760/cma.j.issn.0253-9780.2009.01.002
[16] Wang JW, Fan T, He YJ, et al.  99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis[J]. Breast Cancer Res Treat, 2018, 168(2): 365-370.   doi: 10.1007/s10549-017-4591-z
[17] 王雪鹃, 林保和, 杨志, 等.  新型前哨淋巴结显像剂在乳腺癌中的初步应用[J]. 中华肿瘤杂志, 2006, 28(3): 200-203.   doi: 10.3760/j.issn:0253-3766.2006.03.010
Wang XJ, Lin BH, Yang Z, et al.  Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient[J]. Chin J Oncol, 2006, 28(3): 200-203.   doi: 10.3760/j.issn:0253-3766.2006.03.010